How Investors Are Reacting To Kiniksa (KNSA) KPL-387 Progress And A Fresh Analyst Buy Rating

Simply Wall St.2025-12-24

Earlier in December, Kiniksa Pharmaceuticals International received a Buy rating from a Wells Fargo analyst and released an update on its Phase 2 study of KPL-387 monotherapy in recurrent pericarditis...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2593447833?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2025-12-24 04:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593447833","market":"nz","top_or_hot":-1,"title":"How Investors Are Reacting To Kiniksa (KNSA) KPL-387 Progress And A Fresh Analyst Buy Rating","media":"Simply Wall St.","content":"<div>\n<p>Earlier in December, Kiniksa Pharmaceuticals International received a Buy rating from a Wells Fargo analyst and released an update on its Phase 2 study of KPL-387 monotherapy in recurrent pericarditis...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-knsa/kiniksa-pharmaceuticals-international/news/how-investors-are-reacting-to-kiniksa-knsa-kpl-387-progress\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Investors Are Reacting To Kiniksa (KNSA) KPL-387 Progress And A Fresh Analyst Buy Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Investors Are Reacting To Kiniksa (KNSA) KPL-387 Progress And A Fresh Analyst Buy Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-24 04:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-knsa/kiniksa-pharmaceuticals-international/news/how-investors-are-reacting-to-kiniksa-knsa-kpl-387-progress><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Earlier in December, Kiniksa Pharmaceuticals International received a Buy rating from a Wells Fargo analyst and released an update on its Phase 2 study of KPL-387 monotherapy in recurrent pericarditis...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-knsa/kiniksa-pharmaceuticals-international/news/how-investors-are-reacting-to-kiniksa-knsa-kpl-387-progress\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRGS","symbol_name":"Progress Software Corporation","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-knsa/kiniksa-pharmaceuticals-international/news/how-investors-are-reacting-to-kiniksa-knsa-kpl-387-progress","article_id":"2593447833","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-knsa/kiniksa-pharmaceuticals-international/news/how-investors-are-reacting-to-kiniksa-knsa-kpl-387-progress","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2593447833","pubTimestamp":1766520860,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Earlier in December, Kiniksa Pharmaceuticals International received a Buy rating from a Wells Fargo analyst and released an update on its Phase 2 study of KPL-387 monotherapy in recurrent pericarditis, which aims to transition patients from existing regimens to this new therapy.\nThis combination of a positive analyst view and progress on KPL-387, a key pipeline asset, sharpened investor focus on Kiniksa’s long-term portfolio beyond ARCALYST.\nWe’ll now examine how the latest KPL-387 clinical...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"PRGS":"Progress Software Corporation","ISBC":"投资者银行","KNSA":"Kiniksa Pharmaceuticals Ltd."},"translate_title":"投资者对Kiniksa(KNSA)KPL-387进展和新分析师买入评级的反应","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRGS":1.5,"ISBC":1.5,"KNSA":1.5},"content_text":"Earlier in December, Kiniksa Pharmaceuticals International received a Buy rating from a Wells Fargo analyst and released an update on its Phase 2 study of KPL-387 monotherapy in recurrent pericarditis, which aims to transition patients from existing regimens to this new therapy. This combination of a positive analyst view and progress on KPL-387, a key pipeline asset, sharpened investor focus on Kiniksa’s long-term portfolio beyond ARCALYST. We’ll now examine how the latest KPL-387 clinical update could influence Kiniksa’s earnings outlook, pipeline diversification, and overall investment narrative. Uncover the next big thing with financially sound penny stocks that balance risk and reward.Kiniksa Pharmaceuticals International Investment Narrative RecapTo own Kiniksa, you have to believe ARCALYST can keep funding growth while the pipeline gradually reduces that dependence. The latest KPL-387 Phase 2 update supports that diversification story, but the key near term catalyst still looks to be continued ARCALYST uptake and earnings delivery, while high R&D spend on assets like KPL-387 remains a central risk. The recent upgrades to 2025 net product revenue guidance to US$670 million to US$675 million tie directly into this debate, reinforcing how much of the current outlook still rests on ARCALYST performance even as investors begin to weigh the potential of KPL-387 more seriously. Yet investors should also be aware that if KPL-387 fails to meet expectations in recurrent pericarditis... Read the full narrative on Kiniksa Pharmaceuticals International (it's free!)Kiniksa Pharmaceuticals International's narrative projects $992.0 million revenue and $189.0 million earnings by 2028. This requires 23.3% yearly revenue growth and roughly a $184 million earnings increase from $4.8 million today.Uncover how Kiniksa Pharmaceuticals International's forecasts yield a $54.00 fair value, a 24% upside to its current price.Exploring Other PerspectivesKNSA 1-Year Stock Price Chart Five fair value estimates from the Simply Wall St Community span a wide range, from US$26.39 to US$124.30 per share, showing how differently you might frame upside and downside. Against that backdrop, the dependence on ARCALYST to support both earnings and R&D for KPL-387 makes it especially important to consider several viewpoints before forming your own conviction.Explore 5 other fair value estimates on Kiniksa Pharmaceuticals International - why the stock might be worth 39% less than the current price!Build Your Own Kiniksa Pharmaceuticals International NarrativeDisagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Kiniksa Pharmaceuticals International research is our analysis highlighting 4 key rewards that could impact your investment decision.Our free Kiniksa Pharmaceuticals International research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Kiniksa Pharmaceuticals International's overall financial health at a glance.Ready To Venture Into Other Investment Styles?Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Mobile Infrastructure for Defense and DisasterThe next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.Get the investor briefing before the next round of contractsSponsored On Behalf of CiTechValuation is complex, but we're here to simplify it.Discover if Kiniksa Pharmaceuticals International might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593447833","isCrawlerRequest":true}